Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
- SNY
- REGN
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer.
The application for the monoclonal antibody as the second-line of treatment in the patients was withdrawn "after the companies and the FDA were not able to align on certain post-marketing studies."
The FDA had accepted the supplemental application for priority review in September, with the target action date for the decision on January 30, 2022.
Related: Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC.
Regeneron and Sanofi are still discussing marketing applications with regulatory authorities outside the U.S, the companies said.
Related content: Benzinga's Full FDA Calendar.
The drug is already approved for some types of skin and lung cancer.
Price Action: REGN stock is down 0.43% at $606.09, and SNY is lower by 0.93% at $52.37 on the last check Friday.
See more from Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.